By understanding how these cancer subtypes have managed to escape, or bypass, senescence induction without the loss of p16, not only would the field gain valuable insight into unknown regulation mechanisms and functions of p16, but also there is the opportunity to exploit this overexpression as a new therapeutic strategy. Here, CDKN2A is linked to cancer.